Company Overview of Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of novel RNAi-based therapeutics. The company offers QPI-1002, a synthetic chemically modified siRNA to reduce p53 RNA and protein levels; QPI-1007, a neuro-protective agent for the treatment of optic neuropathies that results in the death of retinal ganglion cells; and PF-655 for the treatment of diabetic macular edema and the other in patients with wet and age-related macular degeneration. It also provides preclinical pipeline targeting unmet medical needs. Quark Pharmaceuticals, Inc. has discovery and development collaboration with Transplant Genomics Inc. The company was formerl...
6501 Dumbarton Circle
Fremont, CA 94555
Founded in 1993
Key Executives for Quark Pharmaceuticals, Inc.
Founder, Chief Executive Officer, President and Director
Senior Vice President of Strategy & Planning
Compensation as of Fiscal Year 2017.
Quark Pharmaceuticals, Inc. Key Developments
Quark Pharmaceuticals, Inc. Presents at Drug Discovery for Rare Diseases Symposium at OPT Congress, Mar-28-2018 01:50 PM
Mar 26 18
Quark Pharmaceuticals, Inc. Presents at Drug Discovery for Rare Diseases Symposium at OPT Congress, Mar-28-2018 01:50 PM. Venue: Boston Marriott Cambridge, Cambridge, Massachusetts, United States. Speakers: Elena Feinstein, Chief Scientific Officer.
Quark Pharmaceuticals, Inc. Presents at CHI’s Third Annual Oligonucleotide Discovery and Delivery Conference, Mar-26-2018 through Mar-28-2018
Mar 26 18
Quark Pharmaceuticals, Inc. Presents at CHI’s Third Annual Oligonucleotide Discovery and Delivery Conference, Mar-26-2018 through Mar-28-2018. Venue: Boston Marriott Cambridge, Cambridge, Massachusetts, United States. Presentation Date & Speakers: Mar-26-2018, Elena Feinstein, Chief Scientific Officer. Mar-28-2018, Elena Feinstein, Chief Scientific Officer.
Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy and Safety Results of QPI-1002, A siRNATargeting P53, for Prevention of Acute Kidney Injury Following Cardiac Surgery
Nov 7 17
Quark Pharmaceuticals Inc. announced that positive results from a Phase 2 clinical study on its lead program QPI-1002 will be presented as an oral abstract at the EuroTIDES conference being held in Vienna AustriaNovember 7-10, 2017. The presentation titled Phase 2 Efficacy And Safety Results Of QPI-1002 (QPI), A siRNA Targeting p53, For Prevention Of Acute Kidney Injury (AKI) Following Cardiac Surgery (CS), will be delivered by Dr. Shai Erlich, CMO and President of Quark Pharmaceuticals US Operations during the 5pm (CET) session on November 8, 2017. About QPI-1002: QPI-1002 is the first systemic siRNA drug to enter human clinical trials and to complete several well-controlled clinical studies with efficacy endpoints that were conducted in hundreds of patients. It is an investigational drug designed to temporarily inhibit the expression of the pro-apoptotic gene, p53, to protect normal cells from death stemming from acute tissue injury. Preclinical studies have shown that p53-targeted siRNAs can protect kidneys from ischemia-reperfusion injury in a variety of clinically relevant animal models. QPI-1002 has been granted Orphan Drug designation in the USA and Europe for prophylaxis of delayed graft function following kidney transplantation. Under an August 2010 agreement, Novartis has an exclusive worldwide license option for the development and commercialization of QPI-1002.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|